Rvl Pharmaceuticals PLC RVLP
We take great care to ensure that the data presented and summarized in this overview for RVL Pharmaceuticals plc is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding RVLP
View allLatest Institutional Activity in RVLP
Top Purchases
Top Sells
About RVLP
RVL Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas in the United States, Argentina, and Hungary. The company is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults. The company was formerly known as Osmotica Pharmaceuticals plc and changed its name to RVL Pharmaceuticals plc in January 2022. RVL Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.
Insider Transactions at RVLP
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 20
2023
|
Foundation Harsaul > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
4,758,899
-49.06%
|
$0
$0.03 P/Share
|
|
Oct 20
2023
|
Altchem LTD > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
4,758,899
-49.06%
|
$0
$0.03 P/Share
|
|
Oct 19
2023
|
Foundation Harsaul > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
9,363,760
-49.12%
|
$0
$0.05 P/Share
|
|
Oct 19
2023
|
Altchem LTD > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
9,363,760
-49.12%
|
$0
$0.05 P/Share
|
|
Oct 18
2023
|
Foundation Harsaul > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
3,421,537
-15.22%
|
$0
$0.06 P/Share
|
|
Oct 18
2023
|
Altchem LTD > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
3,421,537
-15.22%
|
$0
$0.06 P/Share
|
|
Aug 15
2023
|
Avista Healthcare Partners Gp, Ltd. > 10% Shareholder |
SELL
Other acquisition or disposition
|
Indirect |
23,730,864
-100.0%
|
-
|
|
Aug 10
2023
|
Alisa Lask Director |
SELL
Payment of exercise price or tax liability
|
Direct |
12,000
-9.63%
|
$0
$0.49 P/Share
|
|
Jul 05
2023
|
Alisa Lask Director |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+24.31%
|
-
|
|
Jul 05
2023
|
Gregory L Cowan Director |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+30.76%
|
-
|
|
Jul 05
2023
|
Michael J. De Biasi Director |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+50.0%
|
-
|
|
May 18
2023
|
James Schaub EVP and COO |
SELL
Payment of exercise price or tax liability
|
Direct |
5,577
-1.05%
|
$0
$0.87 P/Share
|
|
May 18
2023
|
Christopher Klein General Counsel & Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
5,447
-2.93%
|
$0
$0.87 P/Share
|
|
Jan 27
2023
|
Avista Capital Partners Iii Gp, L.P. > 10% Shareholder |
SELL
Other acquisition or disposition
|
Indirect |
1,032,995
-100.0%
|
-
|
|
Jan 27
2023
|
Sriram Venkataraman Director |
SELL
Other acquisition or disposition
|
Indirect |
1,032,995
-100.0%
|
-
|
|
Jan 27
2023
|
David F Burgstahler Director |
SELL
Other acquisition or disposition
|
Indirect |
1,032,995
-100.0%
|
-
|
|
Jan 24
2023
|
James Schaub EVP and COO |
SELL
Payment of exercise price or tax liability
|
Direct |
9,608
-1.78%
|
$9,608
$1.26 P/Share
|
|
Jan 24
2023
|
Christopher Klein General Counsel & Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
9,608
-4.91%
|
$9,608
$1.26 P/Share
|
|
Aug 10
2022
|
Alisa Lask Director |
BUY
Grant, award, or other acquisition
|
Direct |
75,000
+47.01%
|
-
|
|
Aug 08
2022
|
Avista Healthcare Partners, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
8,000,000
+25.21%
|
$8,000,000
$1.55 P/Share
|